1. Pink Sheet
  2. >>Drug Safety

Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?

 
• By Brenda Sandburg

Even after multiple bellweather wins, Janssen and Bayer still face claims they did not warn doctors about concomitant use with Plavix and aspirin; as case begins in Philadelphia, plaintiff's attorney tells jury the firms were 'silent,' while defense points to doctors' testimony that a different warning would not have changed their prescribing.

court house

PHILADELPHIA – Plaintiff's lawyers hammered one message to the jury in the opening of a Xarelto (rivaroxaban) product liability trial on April 6: Bayer AG and Janssen Pharmaceuticals Inc. were silent about the increased risk of bleeding in those who take the drug with Plavix (clopidogrel) and aspirin, two other blood thinners.

Before beginning his opening statement, Brian Barr, of Levin Papantonio, placed an easel with a large pad of paper in front of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.